I

    Insight Molecular Diagnostics Inc. (IMDX)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $3.92
    -0.21 (-5.08%)

    Market Cap: $135.15M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(13/36)
    Avg Surprise
    -24.71%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.18
    Range$-0.18 - $-0.18
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.18+0.0%
    30d ago$-0.18+0.0%
    7d ago$-0.18+0.0%
    Current$-0.18
    Revenue Consensus
    $543900
    Range$300000 - $940000
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.25
    Range$-0.26 - $-0.25
    2 analysts
    Revenue Consensus
    $-248900
    Range$-808900 - $491100
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.25---
    Sep 26EST
    		-$-0.18---
    Jun 26
    		$-0.23$-0.23+0.00%Beat+23.3%
    Mar 26
    		$-0.12N/A+53.85%Beat+47.8%
    Dec 25
    		$-0.72$-0.24-203.16%Miss+62.7%
    Sep 25
    		$-0.23$-0.24+4.17%Beat+76.5%
    Jun 25
    		$-0.30$-0.24-25.00%Miss+30.2%
    Mar 25
    		$-0.23$-0.25+8.00%Beat+88.9%
    Dec 24
    		$-1.93$-1.12-72.32%Miss-211.3%
    Sep 24
    		$-0.98$-0.44-122.73%Miss-34.2%
    Jun 24
    		$-0.43$-0.37-16.22%Miss-1175.0%
    Mar 24
    		$-2.07$-0.99-109.09%Miss+8.0%
    Sep 23
    		$-0.62$-0.78+20.51%Beat+74.5%
    Jun 23
    		$-0.73$-0.59-23.73%Miss+71.6%
    Mar 23
    		$0.04$-0.08+150.00%Beat+101.2%
    Dec 22
    		$-2.25$-1.60-40.63%Miss-476.9%
    Sep 22
    		$-2.43$-2.33-4.29%Miss+12.0%
    Jun 22
    		$-2.57$-2.00-28.50%Miss+0.4%
    Mar 22
    		$-3.24$-2.00-62.00%Miss-224.0%
    Dec 21
    		$-0.39$-0.12-217.33%Miss-333.3%
    Sep 21
    		$-2.76$-2.00-38.00%Miss-9.1%
    Jun 21
    		$-2.58$-1.84-40.22%Miss+2.3%
    Mar 21
    		$-1.00$-1.88+46.81%Beat+60.0%
    Dec 20
    		$-0.09$-0.11+16.28%Beat+40.0%
    Sep 20
    		$-2.53$-1.84-37.50%Miss-27.8%
    Jun 20
    		$-2.64$-2.05-28.78%Miss-36.1%
    Mar 20
    		$-2.50$-2.12-17.92%Miss-58.2%
    Dec 19
    		$-0.15$-0.09-66.67%Miss+90.6%
    Sep 19
    		$-1.98$-1.64-20.73%Miss-4.8%
    Jun 19
    		$-1.94$-1.72-12.79%Miss+22.7%
    Mar 19
    		$-1.58$-1.72+8.14%Beat+37.5%
    Sep 18
    		$-1.60$-1.73+7.51%Beat+38.5%
    Jun 18
    		$-1.89$-1.87-1.07%Miss+41.8%
    Mar 18
    		$-2.51$-2.40-4.58%Miss-25.5%
    Sep 17
    		$-2.53$-2.53+0.00%Beat-26.5%
    Jun 17
    		$-2.60$-2.33-11.59%Miss-
    Mar 17
    		$-3.25N/AN/ABeat-
    Dec 16
    		$-2.00$-2.00+0.00%Beat-
    Sep 16
    		$-2.00$-2.00+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-3.02EV/EBITDA-1.25x
    Price/FCF-4.67xFCF Yield-21.43%
    Profitability
    Profit Margin0.00%Operating Margin-3815.00%
    ROE-23603.00%ROIC188.98%
    Financial Health
    Debt/Equity-0.03xInterest Coverage-502.66x
    Current Ratio2.00xQuick Ratio1.98x
    Trading Statistics
    Beta1.82Avg Volume208.34K
    52-Week High$8.5152-Week Low$2.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.27
    SMA 20$4.42
    SMA 50$4.79
    SMA 200$5.32
    EMA 10$4.24
    EMA 20$4.38
    EMA 50$4.68
    EMA 200$4.85

    MACD

    Line: -0.19Signal: -0.17Hist: -0.01

    ADX

    ADX: 29.8+DI: 13.3-DI: 27.4

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down52.0
    PSAR$3.56

    Bollinger Bands

    Upper Band$5.11
    Lower Band$3.74
    %B Position3093%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    36.5

    Momentum Oscillators

    Stoch %K45.3
    Stoch %D50.7
    Williams %R-62.0
    ROC (10d)-8.2%
    Momentum-0.35
    CCI (20d)-120.5
    MFI (14d)37.6

    Volatility Measures

    ATR (14d)$0.33(8.3%)
    StdDev (20d)0.34
    Hist Vol96.7%(High)

    Volume Flow

    VWAP$3.97
    OBV-690.9K
    AD Line6.6M
    CMF (20d)-0.149

    Volume Metrics

    Avg Vol (20d)204.1K
    Vol Ratio0.5x
    VWMA (20d)$4.25

    Pivot Points

    R3$4.74
    R2$4.61
    R1$4.37
    Pivot Point$4.24
    S1$4.00
    S2$3.87
    S3$3.63

    Advanced Oscillators

    TSI-15.66
    Ultimate Osc35.7
    KST-119.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$239,000$32,000$1.14M$260,000$518,000$2.14M$1.49M$115,000$104,000$176,000$314,000$429,000
    Cost of Revenue$82,000$17,000$655,000$121,000$180,000$813,000$891,000$65,000$54,000$131,000$453,000$181,000
    Gross Profit$157,000$15,000$484,000$139,000$338,000$1.32M$595,000$50,000$50,000$45,000$-117,000$248,000
    Operating Expenses$11.56M$4.43M$23.92M$11.19M$10.18M$8.12M$34.22M$13.56M$4.68M$9.31M$16.06M$6.76M
    R&D$4.49M$4.95M$5.82M$3.88M$3.27M$2.92M$2.26M$2.82M$2.45M$2.31M$2.55M$2.19M
    SG&A$2.87M$2.99M$2.33M$2.54M$2.65M$3.12M$2.56M$2.56M$2.41M$2.67M$1.75M$2.49M
    Operating Income$-11,402,000$-4,413,000$-23,435,000$-11,048,000$-9,842,000$-6,799,000$-33,627,000$-13,515,000$-4,632,000$-9,267,000$-16,179,000$-6,513,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$20,000$23,000$26,000$29,000$25,000$29,000$30,000$31,000$8,000$15,000$13,000$14,000
    Income Before Tax$-11,260,000$-4,290,000$-22,955,000$-10,854,000$-9,742,000$-6,671,000$-33,511,000$-13,493,000$-4,530,000$-9,129,000$-15,992,000$-6,489,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-11,260,000$-4,290,000$-22,955,000$-10,854,000$-9,742,000$-6,671,000$-33,511,000$-13,493,000$-4,530,000$-9,129,000$-15,992,000$-6,489,000
    EBITDA$-10,575,000$-3,636,000$-22,366,000$-10,241,000$-9,158,000$-6,151,000$-32,918,000$-13,122,000$-4,196,000$-8,779,000$-15,654,000$-6,049,000
    EBIT$-11,240,000$-4,267,000$-22,929,000$-10,825,000$-9,717,000$-6,642,000$-33,481,000$-13,462,000$-4,522,000$-9,114,000$-15,979,000$-6,475,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IMDX

    News

    Insight Molecular Q2FY26 Results: Cash burn rises to $10 million

    Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) reported a Q2 2026 cash burn of $10 million, exceeding its $6 million guidance, primarily due to regulatory review and registry investment timing. Despite this, the adjusted EBITDA loss narrowed to $7.8 million as core spending decreased. The company expects lower cash burn in H2 2026 and targets FDA marketing authorization for Graftasure DX later this year, supported by favorable Medicare reimbursement changes.

    scanx.trade•8/24/26•
    Somewhat-Bearish

    Lucid Capital Markets initiates Insight Molecular stock with buy rating

    Lucid Capital Markets has initiated coverage on Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) with a Buy rating and a price target of $8.00, suggesting an 84% upside from its current stock price. The firm's positive outlook is based on Insight Molecular's decentralized kitted model, which enables local hospitals to perform complex lab tests in-house, offering quicker results and economic benefits. This initiation follows recent mixed Q2 2026 results for IMDX and a reiterated Buy rating for Immunodiagnostics by Needham, highlighting developments in the broader diagnostics sector.

    Investing.com•8/24/26•
    Bullish

    IMDX | Insight Molecular Diagnostics Inc. Financials - Revenue Breakdown

    This page provides a financial overview of Insight Molecular Diagnostics Inc. (IMDX), focusing on its revenue breakdown. It includes sections on Congress trading, insider trading, institutional ownership, corporate lobbying, and patent data, though most sections indicate no recent activity or data for IMDX. The company is described as a pioneering diagnostics technology firm specializing in donor-derived cell-free DNA (dd-cfDNA) testing.

    Quiver Quantitative•8/24/26•
    Neutral

    Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12

    Lake Street has reiterated its Buy rating for Insight Molecular Diagnostics (IMDX.US), while also maintaining its price target of $12. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

    Moomoo•8/18/26•
    Bullish

    Insight Molecular Diagnostics (IMDX) Q2 2026 Earnings Call Transcript

    Insight Molecular Diagnostics (IMDX) reported its Q2 2026 earnings, showing a transition towards becoming a revenue-generating company with its GraftAssureDx product nearing FDA authorization. The company highlighted favorable market shifts due to updated Medicare reimbursement guidelines and strong clinical data. Despite an increased projected cash burn for the second half of 2026, driven by regulatory and registry costs, management expressed confidence in future revenue growth and market expansion, particularly into heart transplant testing and European markets.

    The Globe and Mail•8/18/26•
    Neutral

    Frequently Asked Questions About IMDX

    Does IMDX pay dividends?
    Insight Molecular Diagnostics Inc. (IMDX) does not currently pay a regular dividend.
    What is IMDX's market cap?
    Insight Molecular Diagnostics Inc. (IMDX) has a market capitalization of $135.15M with a current stock price of $3.92.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In